Imaging, Diagnostics, and Biomarkers

Technological advances in imaging, diagnostics, and biomarkers are redefining how respiratory diseases are identified, staged, and monitored. High-resolution CT, functional MRI, and PET scans are now integral in assessing interstitial lung diseases, pulmonary embolism, and malignancies. Molecular and proteomic biomarkers offer early detection potential for conditions like idiopathic pulmonary fibrosis and lung cancer. AI-assisted diagnostic tools are improving accuracy while reducing interpretation times. Furthermore, point-of-care testing and biomarker panels are helping clinicians stratify risk and track therapy responses. The convergence of Imaging, Diagnostics, and Biomarkers is streamlining the clinical pathway and enabling data-driven decision-making in pulmonology. Advances in radiogenomics and breath-based volatile compound detection hint at a future where diagnosis is non-invasive, rapid, and deeply personalized. Collaboration between bioengineers, data scientists, and pulmonologists is essential to translate these innovations into everyday practice.